A clinical trial led by Professor Uwe Platzbecker from the University of Leipzig Medical Center tested a new treatment combination for higher-risk myelodysplastic neoplasms (MDS). Symptoms of MDS include rapid progression, severe symptoms, and a transition to acute leukemia. Only intensive treatments like stem cell transplantation and chemotherapy are available to patients with higher-risk MDS. The new treatment, which combines hypomethylating agents with sabatolimab, a new immunotherapeutic agent, was tested in 127 patients. The combination did not significantly improve response rates or survival, but still showed potential, with a randomized phase 3 trial underway to investigate its benefit in overall patient survival.
Source link
Researching a new treatment option for severe blood disorders of the bone marrow
